Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Thematic (Sector/Industry)

<ul><li>Asian bourses mostly declined as concerns over US tariffs continued to pressure markets.</li><li>The SET had a brief rebound, supported by hospital and banking stocks, before plunging sharply due to a lack of new catalysts and weaker-than-expected 4Q24 earnings.</li><li>Large- cap stocks, including ADVANC, CPALL, GULF, PTTEP, and SCC, led the decline.</li></ul>

Asian bourses mostly declined as concerns over US tariffs continued to pressure markets.The SET had a brief rebound, supported by hospital and banking stocks, before plunging sharply due to a lack of new catalysts and weaker-than-expected 4Q24 earnings.Large- cap stocks, including ADVANC, CPALL, GULF, PTTEP, and SCC, led the decline.

<ul><li>Most Asian bourses rebounded, helping the SET recover, with a buying force flowing into ADVANC, CPALL, GULF, and INTUCH, creating a robust trading atmosphere.</li><li>This was further supported by the positive news of the MPC cutting interest rates in the afternoon, which accelerated the index's rise despite the decline in banking and oil shares.</li><li>The SET surged strongly, with the RSI recovering from the oversold zone and the stochastic climbing, while the index approached the 5- day EMA line at 1,233 points. </li></ul>

Most Asian bourses rebounded, helping the SET recover, with a buying force flowing into ADVANC, CPALL, GULF, and INTUCH, creating a robust trading atmosphere.This was further supported by the positive news of the MPC cutting interest rates in the afternoon, which accelerated the index's rise despite the decline in banking and oil shares.The SET surged strongly, with the RSI recovering from the oversold zone and the stochastic climbing, while the index approached the 5- day EMA line at 1,233 points. 

<ul><li>The SET sank significantly, ranking second after the Indian market, as there were no new driving factors.</li><li>Disappointment with the 4Q24 earnings, particularly the declines in AOT, GULF, INTUCH, TRUE, and banking stocks, led investors to delay their investments, causing the index to hit new lows easily.</li><li>The index fell below 1,236 points. The further it moves along the BB bottom line, the higher the risk of a retreat to 1,220-1,200 points. </li></ul>

The SET sank significantly, ranking second after the Indian market, as there were no new driving factors.Disappointment with the 4Q24 earnings, particularly the declines in AOT, GULF, INTUCH, TRUE, and banking stocks, led investors to delay their investments, causing the index to hit new lows easily.The index fell below 1,236 points. The further it moves along the BB bottom line, the higher the risk of a retreat to 1,220-1,200 points. 

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Ono Pharmaceutical received FDA approval for Romvimza for the treatment of symptomatic tenosynovial giant cell tumor. Shionogi obtains domestic approval for digital therapeutic app, Endeavorride for ADHD.</li>
<li>Samsung Biologics received FDA and European Commission approval for Prolia biosimilar. Celltrion received European approval for Prolia and Eylea biosimilars. Cosette Pharmaceuticals is acquiring Mayne Pharma for A$7.40 per share.</li>
<li>CSPC Pharmaceutical granted an exclusive license to Radiance Biopharma to develop and commercialize antibody drug conjugates SYS6005 in selected geographies. Cipla received FDA approval for anti-cancer drug Nilotinib capsules.</li>
</ul>


Ono Pharmaceutical received FDA approval for Romvimza for the treatment of symptomatic tenosynovial giant cell tumor. Shionogi obtains domestic approval for digital therapeutic app, Endeavorride for ADHD.
Samsung Biologics received FDA and European Commission approval for Prolia biosimilar. Celltrion received European approval for Prolia and Eylea biosimilars. Cosette Pharmaceuticals is acquiring Mayne Pharma for A$7.40 per share.
CSPC Pharmaceutical granted an exclusive license to Radiance Biopharma to develop and commercialize antibody drug conjugates SYS6005 in selected geographies. Cipla received FDA approval for anti-cancer drug Nilotinib capsules.


APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne

<ul><li>We expect certain healthcare service stocks and healthcare-related stocks to rebound and outperform the market, driven by the rapid spread of influenza.</li><li>This is likely to boost health awareness and increase demand for healthcare services. At the same time, the previous decline in these stocks has made their valuations more attractive.</li><li>For healthcare stocks, we recommend BDMS, PR9, CHG, and BCH. Meanwhile, healthcare-related stocks that could benefit from positive sentiment include STGT, MEGA, and OKJ.</li></ul>

We expect certain healthcare service stocks and healthcare-related stocks to rebound and outperform the market, driven by the rapid spread of influenza.This is likely to boost health awareness and increase demand for healthcare services. At the same time, the previous decline in these stocks has made their valuations more attractive.For healthcare stocks, we recommend BDMS, PR9, CHG, and BCH. Meanwhile, healthcare-related stocks that could benefit from positive sentiment include STGT, MEGA, and OKJ.

Influenza Outbreak Supporting Recovery of Healthcare Stocks - FEBRUARY 20, 2025

Thailand

Bangkok Dusit Medical Services Public Company Limited operates hospital networks. The Firm manages hospital groups and wellness clinics to provide cost-efficiencies, high-quality, and best-outcomes, as well as pharmaceutical businesses, insurance, information technology, and pathology services. Bangkok Dusit Medical Services focuses on patients and healthcare professionals.

Bangkok Dusit Medical Services (BDMS-R TB)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bangkok Dusit Medical Services (BDMS-R TB)

Technical Analysis - FEBRUARY 28, 2025

The SET had a brief rebound, supported by hospital and banking stocks, before plunging sharply due to a lack of new catalysts and weaker-than...

Krungthai XSpring

Technical Analysis - FEBRUARY 27, 2025

Most Asian bourses rebounded, helping the SET recover, with a buying force flowing into ADVANC, CPALL, GULF, and INTUCH, creating a robust trading...

Krungthai XSpring

Technical Analysis - February 25, 2025

The SET sank significantly, ranking second after the Indian market, as there were no new driving factors. Disappointment with the 4Q24 earnings,...

Krungthai XSpring

APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

Influenza Outbreak Supporting Recovery of Healthcare Stocks - FEBRUARY 20, 2025

We expect certain healthcare service stocks and healthcare-related stocks to rebound and outperform the market, driven by the rapid spread of...

Krungthai XSpring

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)